�����ƽ��

Dr. Daniela Mora Ortiz is a Scientist in the Product and Scientific Support department at �����ƽ�� Technologies, specializing in epithelial cell biology and cell and gene therapy. She earned her medical degree in Mexico City and completed her specialization in Hematology and Hemotherapy at Hospital Vall d’Hebron in Barcelona, Spain. After her clinical training, she conducted research on pluripotent stem cell differentiation toward hematopoietic lineages and on lung differentiation, gaining expertise in stem cell biology and translational applications. Since joining �����ƽ�� in 2017, she has held roles in education, lab management, and scientific support, where she has provided training, advanced technical support, troubleshooting, and consultation to researchers worldwide. In her current role, she supports customers, distributors, and internal teams on epithelial cell biology portfolios while contributing to cross-functional initiatives in cell and gene therapy. She also plays an active role in educational programs, developing and delivering training to enable scientists to advance their research. Over the past two years, she has focused extensively on cell and gene therapy, combining her medical and scientific expertise. Dr. Mora Ortiz is passionate about advancing hematology and epithelial biology research and about enabling scientists to drive innovation in cell and gene therapy.

Josh Woodburn is a Manager in the Regulatory Affairs, Ancillary Materials group at �����ƽ�� Technologies. He and his team provide regulatory support and multi-region governance of media and reagents intended for use as ancillary materials in cell and gene therapy development. Josh earned a Masters degree in Pharmaceutical Bioengineering at the University of Washington, specializing in clinical drug and device development. He has participated at various levels of clinical development phases, including direct contributions and support for pre-clinical startup decision-making through successful Biologics License Applications and post-market registrations.

Mina Ordobadi is a Regulatory Affairs Specialist in the Quality Assurance department at �����ƽ�� Technologies. Mina has experience from research to market, including interactions with the US FDA and Health Canada. In her current role, she performs regulatory analysis and provides support for media and reagents intended for use as ancillary materials, including direct regulatory submission. Mina earned a BSc in Biochemistry from Simon Fraser University and a PhD in Biochemistry from the University of British Columbia.

Stephanie Hastings is a Services for Cell Therapy Program Manager at �����ƽ�� Technologies. In this role, Stephanie has worked with dozens of sponsors to help qualify �����ƽ�� products as ancillary materials for use in cell and gene therapy manufacturing from early clinical trials through commercial approval. Stephanie has deep expertise in the design and delivery of customized solutions to meet the specific clinical requirements of small biotechs, large pharmaceutical companies and contract development and manufacturing organizations. She obtained her BSc in Biomedical, Health and Life Sciences and MSc in Biotechnology and Business in Dublin, Ireland, where she focused on translational research in human health and disease and commercialization of novel biotechnological solutions.